Fast-track your oncology drug candidate development with OrganoidXplore, our advanced platform optimized for comprehensive organoid panel screening. This assay-ready service processes up to 50 models in as little as 6 weeks ensuring your research stays ahead of the curve with rapid, data-driven decision making. At the heart of this premier service is an extensive repository of thoroughly characterized PDO and PDXO models including significant mutational profiles. The service has been designed to provide detailed measurements of drug responses in both tumor and normal organoids. Moreover, it facilitates exploration into new cancer indications backed by validated targets and advanced biomarker analysis.
|Model Selection Diversity
|Leverage 50 well-characterized PDO and PDXO models with varied genetic backgrounds and mutations such as KRAS, BRAF, and EGFR, enriching your research diversity.
|Multiple Panel Options
|Choose from Full Panel, KRAS Panel, Lung Panel, CRC Panel, or Flexible Panel (20+ model selection).
|Depend on rigorously validated and quality-assured organoid models, SNP verified and mycoplasma tested. Underpinned with extensive characterization against standard of care agents.
|7 Cancer Type Models
|Explore and test efficacy across a diverse range of cancer types, including lung, breast, ovarian, colorectal, pancreatic, cervical, melanoma.
|Investigate off-target effects with 6 matched normal/disease pairs, enabling a thorough comparative analysis.
|PDX Model Selection
|Transition effortlessly into in vivo studies with the majority of our models. Elect suitable Patient Derived Xenograft models to validate your efficacy studies and accurately stratify patient responses.
Receive an exhaustive Customer Report featuring 9-point dose-response curves, IC50s, study design, control performance, ensuring you have all the data needed to proceed confidently in your research.